Global Circular Mrna Manufacturing Market
Market Size in USD Billion
USD
1.28 Billion
USD
4.28 Billion
2025
2033
 Forecast Period |
2026 - 2033 |
 Market Size (Base Year) |
USD 1.28 Billion |
 Market Size (Forecast Year) |
USD 4.28 Billion |
 CAGR |
% |
| Major Markets Players |
|
Circular mRNA Manufacturing Market Overview
As per Data Bridge Market Research analysis, the circular mRNA manufacturing market was valued at USD 1.28 billion in 2025 and is projected to reach USD 4.28 billion by 2033, growing at a CAGR of 16.30% from 2026 to 2033. The market is experiencing consistent growth driven by the emergence of next-generation RNA modalities, increasing investments in RNA therapeutics manufacturing, and expanding demand for scalable GMP manufacturing capabilities for circular RNA-based vaccines and therapeutics.
The superior stability, prolonged protein expression, and enhanced resistance to exonuclease degradation offered by circular mRNA compared to conventional linear mRNA are accelerating its adoption across vaccine development, oncology, and protein replacement therapies. Increasing research collaborations, expanding CDMO manufacturing infrastructure, and growing investments in RNA platform technologies are further supporting the commercialization of circular mRNA manufacturing for clinical and future large-scale therapeutic applications
Market Size & Forecast
- Global Market Value (2025): USD 1.28 Billion
- Expected Market Value (2033): USD 4.28 Billion
- Forecast CAGR (2026–2033): 16.30%
- Leading Region in 2025: North America
- Fastest Growing Region: Asia Pacific
Key Market Trends & Insights
- North America dominated the global circular mRNA (circRNA) manufacturing market with the largest revenue share of 45.16% in 2025, supported by robust RNA therapeutics research, strong biotechnology and pharmaceutical presence, and substantial government funding for RNA innovation
- The enzymatic circularization segment led the market with a 50.2% share in 2025, driven by its high circularization efficiency, scalability, and compatibility with GMP manufacturing workflows
- Asia-Pacific is expected to be the fastest-growing regional market, projected to expand at a CAGR of 20.8% during the forecast period, fueled by expanding biotechnology ecosystems, increasing R&D investments, and growing adoption of RNA therapeutics across China, India, Japan, and South Korea
- Self-splicing is the fastest-growing technology type, projected to register a CAGR of 23.4%, reflecting the surge in interest in next-generation RNA engineering platforms.
- The in vitro transcription (IVT) segment dominated the manufacturing process category with a 33.6% revenue share in 2025, led by its essential role in generating high-quality RNA transcripts required for downstream circularization
- Cancer immunotherapy accounted for 36.4% of the market, preferred by the growing use of circular RNA platforms for developing next-generation cancer vaccines and immune-modulating therapeutics
- The protein replacement therapy segment is the fastest-growing application category, with a CAGR of 25.2%, driven by increasing interest in using circular RNA to produce therapeutic proteins for extended durations.
Report Scope and Circular mRNA Manufacturing Market Segmentation
|
Attributes |
Circular mRNA Manufacturing Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Circular mRNA Manufacturing Market Trends
Trend: Increasing Development of Next-Generation Circular RNA Therapeutics
Biopharmaceutical companies are increasingly investing in circular RNA platforms to develop next-generation vaccines, oncology therapies, protein replacement medicines, and in vivo cell therapies that provide longer protein expression and improved molecular stability compared with conventional linear mRNA. Advances in circularization technologies, lipid nanoparticle delivery systems, and GMP manufacturing capabilities are accelerating clinical translation while enabling scalable commercial production of circular RNA therapeutics across multiple disease areas. For instance, in May 2024, Orna Therapeutics acquired ReNAgade Therapeutics to combine circular RNA engineering with advanced delivery technologies, strengthening capabilities for next-generation RNA therapeutic manufacturing and development.
This trend is expected to accelerate commercialization and expand manufacturing capacity for circular RNA therapeutics globally.
Circular mRNA Manufacturing Market Dynamics
Key Market Driver: Growing Demand for Stable and Long-Lasting RNA Therapeutics
The superior stability, prolonged protein expression, and enhanced resistance to exonuclease degradation offered by circular RNA have significantly increased demand for manufacturing platforms capable of producing high-quality clinical-grade products. Pharmaceutical companies, biotechnology firms, and CDMOs are expanding process development, GMP manufacturing, and analytical capabilities to support growing pipelines of circular RNA vaccines and therapeutics targeting cancer, rare diseases, and genetic disorders. For instance, in January 2025, Orna Therapeutics and Simnova Biotech expanded their strategic collaboration to develop BCMA-targeted circular RNA therapeutics, reinforcing increasing demand for scalable manufacturing and commercialization capabilities.
This driver is expected to strengthen investments in GMP manufacturing infrastructure and accelerate clinical development of circular RNA medicines.
Key Restraint/Challenge: Complex Manufacturing Processes and Limited GMP Manufacturing Capacity
A major challenge in the circular mRNA manufacturing market is the technical complexity associated with RNA circularization, purification, analytical characterization, and large-scale GMP production while maintaining high purity, consistency, and regulatory compliance. Limited availability of specialized manufacturing infrastructure and validated production platforms increases production costs and creates capacity constraints for clinical and commercial supply. For instance, in December 2025, uBriGene Biosciences partnered with Circurna to expand process development, analytical testing, scale-up, and GMP manufacturing for circular RNA therapeutics, highlighting the industry's need for specialized manufacturing expertise and infrastructure.
This challenge is expected to encourage additional investment in dedicated GMP manufacturing facilities and advanced RNA production technologies.
Key Market Opportunity: Expansion of GMP CDMO Services for Circular RNA Therapeutics
The rapid expansion of circular RNA pipelines is creating significant opportunities for contract development and manufacturing organizations to provide end-to-end services including process optimization, analytical testing, lipid nanoparticle formulation, GMP manufacturing, and regulatory support. Increasing outsourcing by biotechnology and pharmaceutical companies is driving demand for scalable manufacturing platforms capable of supporting clinical and commercial production of circular RNA therapeutics. For instance, in June 2025, Circio Holding ASA and NeoRegen Biotech advanced their circular RNA delivery collaboration into the in vivo preclinical stage after successful in vitro proof-of-concept studies, marking progress toward the clinical development and future commercialization of circular RNA therapeutics.
This opportunity is expected to accelerate pipeline expansion and increase demand for scalable circular RNA manufacturing technologies.
Circular mRNA Manufacturing Market Scope
The circular mRNA manufacturing market is segmented on the basis of technology, manufacturing process, application, and end user.
- By Technology
On the basis of technology, the circular mRNA manufacturing market is segmented into enzymatic circularization, self-splicing, and chemical circularization. The enzymatic circularization segment dominated the market with an estimated 50.2% share in 2025, owing to its high circularization efficiency, scalability, and compatibility with GMP manufacturing workflows. This approach utilizes enzymatic ligation systems to generate highly stable circular RNA molecules with improved product consistency and yield. The technology is widely used by biotechnology companies and CDMOs because it supports large-scale production while maintaining RNA integrity. Growing demand for clinical-grade circular RNA therapeutics and vaccines is further strengthening adoption. Continuous advancements in ligase engineering and process optimization are improving manufacturing performance and productivity. Its proven suitability for commercial-scale therapeutic development continues to make it the leading technology segment globally.
The self-splicing segment is projected to register the fastest growth at an estimated CAGR of 23.4% from 2026 to 2033, driven by increasing interest in next-generation RNA engineering platforms. Self-splicing technologies utilize ribozyme-mediated circularization mechanisms that reduce dependence on external enzymes and simplify manufacturing workflows. These systems are gaining attention for their ability to produce highly pure circular RNA constructs with enhanced translational efficiency. Expanding research into oncology, gene therapy, and protein replacement applications is accelerating adoption. Ongoing innovation in ribozyme design and sequence optimization is improving process reliability and scalability. Growing investment in advanced RNA platforms is expected to further support rapid growth of this segment.
- By Manufacturing Process
On the basis of manufacturing process, the circular mRNA manufacturing market is segmented into template DNA preparation, in vitro transcription (IVT), circularization, purification, and quality control & fill-finish. The in vitro transcription (IVT) segment led the market with an estimated 33.6% share in 2025, driven by its essential role in generating high-quality RNA transcripts required for downstream circularization. IVT serves as the foundational production step for virtually all circular RNA manufacturing workflows. Increasing demand for therapeutic-grade RNA molecules has significantly increased investment in optimized transcription systems and enzyme technologies. Advances in transcription efficiency and yield enhancement are supporting large-scale production requirements. The process also enables flexible manufacturing across multiple therapeutic applications. Its indispensable role throughout the RNA production chain continues to strengthen its market leadership.
The circularization segment is expected to witness the fastest growth at an estimated CAGR of 24.1% from 2026 to 2033, driven by increasing focus on improving RNA stability, durability, and protein expression performance. Circularization is the defining manufacturing step that differentiates circular RNA from conventional linear mRNA products. Growing commercialization of circular RNA therapeutics is creating substantial demand for efficient circularization technologies. Manufacturers are investing heavily in novel enzymatic and ribozyme-based approaches to improve yield and reduce production costs. Continuous innovation is enhancing process scalability and regulatory compliance. The increasing importance of circular RNA-specific manufacturing capabilities is expected to accelerate growth in this segment.
- By Application
On the basis of application, the circular mRNA manufacturing market is segmented into vaccines, cancer immunotherapy, protein replacement therapy, gene editing, rare diseases, and research applications. The cancer immunotherapy segment dominated the market with an estimated 36.4% share in 2025, driven by the growing use of circular RNA platforms for developing next-generation cancer vaccines and immune-modulating therapeutics. Circular RNA offers prolonged protein expression and enhanced stability, making it particularly attractive for oncology applications. Increasing investments from biotechnology companies and pharmaceutical manufacturers are supporting clinical development programs. The rising global burden of cancer is encouraging demand for innovative treatment modalities. Ongoing advances in targeted delivery technologies are further improving therapeutic potential. Strong research activity and expanding clinical pipelines continue to reinforce this segment’s leading position.
The protein replacement therapy segment is projected to register the fastest growth at an estimated CAGR of 25.2% from 2026 to 2033, fueled by increasing interest in using circular RNA to produce therapeutic proteins for extended durations. The technology offers advantages over traditional mRNA by enabling sustained protein expression and reducing dosing frequency. Growing development efforts targeting metabolic disorders, genetic diseases, and enzyme deficiencies are supporting adoption. Researchers are increasingly exploring circular RNA as an alternative to recombinant protein therapies. Expanding investment in rare disease treatment platforms is further driving growth. Continuous advancements in delivery systems are expected to accelerate commercial adoption of this segment.
- By End User
On the basis of end user, the circular mRNA manufacturing market is segmented into biopharmaceutical companies, biotechnology companies, CDMOs/CMOs, and academic & research institutes. The biopharmaceutical companies segment led the market with a 59.55% share in 2024, driven by substantial investments in RNA therapeutic development, clinical trials, and commercial manufacturing infrastructure. These organizations possess the financial resources and technical expertise necessary to advance circular RNA programs through regulatory pathways. Increasing focus on oncology, vaccines, and rare disease therapies is driving manufacturing demand. Strategic partnerships with technology providers and contract manufacturers are further supporting market expansion. Growing competition to develop differentiated RNA-based therapeutics is accelerating investment activity. Their strong commercialization capabilities continue to position this segment as the largest end-user category.
The CDMOs/CMOs segment is expected to witness the fastest growth at an estimated CAGR of 21.4% from 2026 to 2033, driven by increasing outsourcing of process development, analytical testing, and GMP manufacturing services. Many biotechnology companies lack the infrastructure required for large-scale circular RNA production and therefore rely on specialized manufacturing partners. Rising demand for flexible manufacturing capacity is creating significant opportunities for contract service providers. CDMOs are expanding their RNA technology platforms and production facilities to address growing customer requirements. Increasing complexity of regulatory compliance is further encouraging outsourcing strategies. The expanding circular RNA therapeutic pipeline is expected to make this the fastest-growing end-user segment globally.
Circular mRNA Manufacturing Market Regional Analysis
North America dominated the global circular mRNA (circRNA) manufacturing market with the largest revenue share of 45.16% in 2025, supported by robust RNA therapeutics research, strong biotechnology and pharmaceutical presence, and substantial government funding for RNA innovation. The region also benefits from extensive funding for next-generation RNA technologies, well-established clinical development infrastructure, and a growing number of strategic collaborations focused on circular RNA therapeutics. Increasing adoption of advanced manufacturing platforms, lipid nanoparticle delivery technologies, and GMP production capabilities is accelerating market expansion. Rising investments in oncology, rare disease, and vaccine development programs are further supporting demand for large-scale circular RNA manufacturing. Continuous innovation in RNA engineering and expanding commercialization activities continue to strengthen North America's leadership position in the global market.
U.S. Circular mRNA Manufacturing Market Insight
The U.S. circular mRNA manufacturing market is witnessing strong growth due to rising investments in RNA therapeutics, expanding clinical development programs, and increasing demand for next-generation RNA manufacturing capabilities. The country’s mature biotechnology ecosystem, strong venture capital activity, and concentration of leading RNA technology developers are driving demand across vaccine, oncology, and rare disease applications. In addition, growing emphasis on scalable GMP manufacturing and advanced delivery technologies is accelerating commercialization activities. In May 2024, Orna Therapeutics acquired ReNAgade Therapeutics to strengthen its circular RNA platform and delivery capabilities, creating one of the industry's most comprehensive circular RNA development ecosystems. This development highlights the increasing investment and innovation activity supporting market expansion in the United States.
Europe Circular mRNA Manufacturing Market Insight
The Europe circular mRNA manufacturing market remains a major contributor to global revenue, driven by strong research funding, technological innovation, and increasing focus on RNA-based therapeutics. The widespread presence of biotechnology companies, academic research institutions, and advanced manufacturing facilities is supporting market expansion across the region. Increasing investments in circular RNA technologies, coupled with favorable regulatory support and collaborative research programs, continue to enhance market development. Circio Holding ASA, headquartered in Norway, has advanced multiple circular RNA development programs and expanded strategic collaborations focused on next-generation RNA therapeutics. Such initiatives continue to strengthen Europe’s position within the global circular RNA ecosystem
U.K. Circular mRNA Manufacturing Market Insight
The U.K. circular mRNA manufacturing market is experiencing steady growth, supported by rising adoption of RNA technologies in therapeutic development, increasing research investments, and expanding biotechnology innovation. Growing demand for advanced manufacturing solutions and translational medicine programs is contributing to market growth. Furthermore, collaboration between biotechnology companies, universities, and research organizations is improving development efficiency and accelerating commercialization activities. The U.K. government continues to support RNA innovation through funding initiatives under UK Research and Innovation (UKRI), strengthening domestic capabilities in advanced RNA therapeutics and manufacturing technologies. These efforts are positioning the U.K. as an important innovation center within the European RNA industry.
Germany Circular mRNA Manufacturing Market Insight
The Germany circular mRNA manufacturing market is expanding steadily due to the country’s strong biotechnology infrastructure, advanced manufacturing capabilities, and increasing investment in RNA therapeutic research. Pharmaceutical companies, biotechnology firms, and research institutes are increasingly focusing on novel RNA platforms for oncology, rare disease, and vaccine applications. Continuous advancements in RNA engineering technologies and process development capabilities are further supporting market growth. For instance, Germany remains one of Europe's leading biotechnology markets and is home to BioNTech, which continues to invest heavily in next-generation RNA technologies and manufacturing infrastructure. Strong industrial expertise and innovation capacity continue to support market expansion across the country.
Asia-Pacific Circular mRNA Manufacturing Market Insight
The Asia-Pacific circular mRNA manufacturing market is expected to witness rapid growth, driven by expanding biotechnology sectors, rising healthcare investments, and increasing demand for innovative therapeutic platforms across countries such as China, Japan, South Korea, and India. Growing awareness regarding RNA therapeutics, rising government support for biotechnology innovation, and increasing investment in manufacturing infrastructure are supporting regional market expansion. In addition, expanding clinical research activities and strategic collaborations are accelerating adoption across commercial and academic sectors. In March 2025, the Asian Development Bank (ADB) approved the REVITALIZE initiative to strengthen regulatory ecosystems and manufacturing capacity for vaccines, therapeutics, and diagnostics across Asia-Pacific, supporting long-term regional biomanufacturing capabilities. These initiatives are expected to further accelerate regional commercialization and manufacturing expansion
Japan Circular mRNA Manufacturing Market Insight
The Japan circular mRNA manufacturing market is witnessing consistent growth due to rising investments in advanced RNA therapeutics, biotechnology innovation, and regenerative medicine research. Pharmaceutical manufacturers, biotechnology companies, and research institutes are increasingly exploring circular RNA technologies for therapeutic development and precision medicine applications. Moreover, increasing focus on next-generation biologics and advanced delivery technologies is further contributing to market growth. Japan's government has expanded support for advanced biopharmaceutical and RNA technology research through national biotechnology and healthcare innovation programs. These initiatives are strengthening the country's position within the Asia-Pacific RNA therapeutics landscape.
China Circular mRNA Manufacturing Market Insight
The China circular mRNA manufacturing market is growing rapidly, driven by expanding biotechnology infrastructure, increasing government support for innovative therapeutics, and rising investment in RNA drug development. Growing adoption of advanced RNA manufacturing technologies across biotechnology and pharmaceutical companies is significantly boosting market demand. In addition, increasing clinical research activity, strong domestic innovation, and rapid expansion of biopharmaceutical manufacturing capacity are positioning China as one of the fastest-growing markets globally. In October 2024, RiboX Therapeutics announced that its circular RNA therapeutic candidate RXRG001 received U.S. FDA clearance for an Investigational New Drug (IND) application, marking a major milestone for circular RNA therapeutics and highlighting China's growing contribution to global RNA innovation. Continued expansion of clinical research and manufacturing capabilities is expected to further accelerate market growth.
Circular mRNA Manufacturing Market Share
The circular mRNA manufacturing industry is primarily led by well-established companies, including:
- Orna Therapeutics, Inc. (U.S.)
- Circio Holding SA (Norway)
- CirCode Biomed Co., Ltd. (China)
- Arcturus Therapeutics Inc. (U.S.)
- Moderna, Inc. (U.S.)
- BioNTech SE (Germany)
- CureVac SE (Germany)
- TriLink BioTechnologies, (U.S.)
- Aldevron, LLC (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA (Germany)
- Danaher Corporation (U.S.)
- Lonza Group AG (Switzerland)
- Catalent, Inc. (U.S.)
- WuXi AppTec Co., Ltd. (China)
- GenScript Biotech Corporation (China)
- Creative Biolabs (U.S.)
- Charles River. (U.S.)
- Eurofins Scientific SE (Luxembourg)
Latest Developments in Circular mRNA Manufacturing Market
- In July 2025, CD Formulation launched its customizable circular RNA (circRNA) synthesis service to support research, therapeutic development, vaccine development, and gene regulation studies. The newly introduced service provides high-quality circular RNA synthesis capabilities with advanced design and quality control processes to address the growing demand for stable RNA molecules. This launch expands access to specialized circRNA manufacturing services and supports researchers and biotechnology companies developing next-generation RNA therapeutics
- In May 2025, CirCode Biomed announced that its circular RNA therapeutic candidate HM2002 received U.S. FDA Investigational New Drug (IND) clearance for ischemic heart disease, marking a major milestone in the clinical development of circular RNA medicines. HM2002 became one of the first circular RNA drugs to advance into patient administration, demonstrating the potential of circRNA platforms for regenerative medicine applications. This development highlights the transition of circular RNA technologies from research platforms toward clinical-stage therapeutic products
- In March 2025, RiboX Therapeutics announced the first patient dosing of RXRG001 in its Phase I/IIa clinical trial, representing the advancement of a circular RNA therapeutic into first-in-human clinical evaluation. RXRG001 is being developed for radiation-induced xerostomia and hyposalivation, demonstrating the application potential of circular RNA technology beyond conventional mRNA therapeutics. This clinical milestone strengthens industry confidence in circular RNA platforms and supports further investment in manufacturing capabilities for clinical-stage RNA products
- In May 2024, Orna Therapeutics announced the acquisition of ReNAgade Therapeutics to expand its circular RNA platform and delivery technology capabilities. The acquisition combined complementary expertise in circular RNA engineering, RNA delivery systems, and therapeutic development to accelerate the creation of next-generation RNA medicines. This strategic expansion supports the development of integrated circular RNA platforms for future clinical and commercial manufacturing applications
- In January 2024, Chimerna Therapeutics received a U.S. National Institutes of Health (NIH) Small Business Innovation Research (SBIR) award to develop a yeast-based circular RNA manufacturing platform. The project focused on overcoming key challenges associated with circRNA synthesis and purification by developing scalable production technologies for research, therapeutic, and diagnostic applications. This development highlights increasing efforts to establish efficient manufacturing platforms capable of supporting future circular RNA commercialization
SKU-
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
